Advertisement

Testosterone Replacement Therapy

  • G. Rastrelli
  • Y. Reisman
  • S. Ferri
  • O. Prontera
  • A. Sforza
  • M. Maggi
  • G. Corona
Chapter

Abstract

Male hypogonadism (HG) can be defined according to its etiology as primary (pHG) when caused by any diseases affecting the testes, or as secondary (sHG) when due to a pituitary or hypothalamic dysfunction. Both fertility and testosterone (T) can be theoretically restored in sHG by removing the precipitating cause and/or by appropriate endocrine therapy. Conversely, only T treatment can be offered to patients with pHG. Symptoms and signs are quite similar independent of the underlying causes. Conversely, the phenotype of the hypogonadal patient is more often affected by the age of hypogonadism onset. Late-onset hypogonadism (LOH) that occurs in adulthood is probably the most common form of HG. In this chapter, the criteria defining LOH and the available T formulations along with their outcomes and main important side effects are analyzed in detail.

Testosterone replacement therapy (TRT) can be administered with different modalities including oral, transdermal, and injectable formulations. The available meta-analyses show that TRT is able to improve sexual function and body composition whereas the data on the risk of bone fractures, mood, and cognition are more conflicting. Available evidence indicates that cardiovascular (CV) and venous thromboembolism risk are not major issues and that prostate safety is guaranteed when TRT is prescribed according to current guidelines. The risk of increased hematocrit is mainly limited to the use of short-term injectable preparations.

References

  1. 1.
    Corona G, Rastrelli G, Vignozzi L, Maggi M. Emerging medication for the treatment of male hypogonadism. Expert Opin Emerg Drugs. 2012;17:239–59.CrossRefGoogle Scholar
  2. 2.
    Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl. 2012;14:251–9.CrossRefGoogle Scholar
  3. 3.
    Lenzi A, Balercia G, Bellastella A, Colao A, Fabbri A, Foresta C, Galdiero M, Gandini L, Krausz C, Lombardi G, Lombardo F, Maggi M, Radicioni A, Selice R, Sinisi AA, Forti G. Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism. J Endocrinol Investig. 2009;32:934–8.CrossRefGoogle Scholar
  4. 4.
    Corona G, Maseroli E, Rastrelli G, Sforza A, Forti G, Mannucci E, Maggi M. Characteristics of compensated hypogonadism in patients with sexual dysfunction. J Sex Med. 2014;11:1823–34.CrossRefGoogle Scholar
  5. 5.
    Giannetta E, Gianfrilli D, Barbagallo F, Isidori AM, Lenzi A. Subclinical male hypogonadism. Best Pract Res Clin Endocrinol Metab. 2012;26:539–50.CrossRefGoogle Scholar
  6. 6.
    Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab. 2013;27:557–79.CrossRefGoogle Scholar
  7. 7.
    Corona G, Rastrelli G, Maggi M. The pharmacotherapy of male hypogonadism besides androgens. Expert Opin Pharmacother. 2015;6:369–87.CrossRefGoogle Scholar
  8. 8.
    Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123–35.CrossRefGoogle Scholar
  9. 9.
    Rastrelli G, Corona G, Tarocchi M, Mannucci M, Maggi M. How to define hypogonadism? Results from a population of men consulting for sexual dysfunction. J Endocrinol Investig. 2016;39:473–84.CrossRefGoogle Scholar
  10. 10.
    Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab. 2017;102:1067–75.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Corona G, Maseroli E, Rastrelli G, Francomano D, Aversa A, Hackett GI, Ferri S, Sforza A, Maggi M. Is late-onset hypogonadotropic hypogonadism a specific age-dependent disease, or merely an epiphenomenon caused by accumulating disease-burden? Minerva Endocrinol. 2016;41:196–210.PubMedGoogle Scholar
  12. 12.
    Corona G, Bianchini S, Sforza A, Vignozzi L, Maggi M. Hypogonadism as a possible link between metabolic diseases and erectile dysfunction in aging men. Hormones (Athens). 2015;14:569–78.Google Scholar
  13. 13.
    Corona G, Vignozzi L, Sforza A, Mannucci E, Maggi M. Obesity and late-onset hypogonadism. Mol Cell Endocrinol. 2015;418:120–33.CrossRefGoogle Scholar
  14. 14.
    Corona G, Maggi M. Perspective: regulatory agencies’ changes to testosterone product labeling. J Sex Med. 2015;12:1690–3.CrossRefGoogle Scholar
  15. 15.
    Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Androl. 2009;32:1–10.CrossRefGoogle Scholar
  16. 16.
    Khera M, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, McCullough A, Morgentaler A, Torres LO, Salonia A. Diagnosis and treatment of testosterone deficiency: recommendations from the fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13:1787–804.CrossRefGoogle Scholar
  17. 17.
    Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y, Morgentaler A. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18:5–15.CrossRefGoogle Scholar
  18. 18.
    Nieschlag E, Nieschlag S. Testosterone deficiency: a historical perspective. Asian J Androl. 2014;16:161–8.CrossRefGoogle Scholar
  19. 19.
    Nieschlag E, Vorona E. Mechanisms in endocrinology: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. Eur J Endocrinol. 2015;173:R47–58.CrossRefGoogle Scholar
  20. 20.
    Nieschlag E. Current topics in testosterone replacement of hypogonadal men. Best Pract Res Clin Endocrinol Metab. 2015;29:77–90.CrossRefGoogle Scholar
  21. 21.
    Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018;6:77–85.CrossRefGoogle Scholar
  22. 22.
    Corona G, Maseroli E, Maggi M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother. 2014;15:1903–26.CrossRefGoogle Scholar
  23. 23.
    Wang C, Swerdloff RS. Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J Clin Endocrinol Metab. 2002;87:1462–6.CrossRefGoogle Scholar
  24. 24.
    Swerdloff RS, Wang C. Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent. Bailliere Clin Endocrinol Metab. 1998;12:501–6.CrossRefGoogle Scholar
  25. 25.
    Choi SK, Han SW, Kim DH, et al. Transdermal dihydrotestosterone therapy and its effects on patients with microphallus. J Urol. 1993;150:657–60.CrossRefGoogle Scholar
  26. 26.
    Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol. 2000;164:371–5.CrossRefGoogle Scholar
  27. 27.
    Corona G, Rastrelli G, Morgentaler A, Sforza A, Mannucci E, Maggi M. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol. 2017;72:1000–11.CrossRefGoogle Scholar
  28. 28.
    Tsertsvadze A, Fink HA, Yazdi F, MacDonald R, Bella AJ, Ansari MT, Garritty C, Soares-Weiser K, Daniel R, Sampson M, Fox S, Moher D, Wilt TJ. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009;151:650–61.CrossRefGoogle Scholar
  29. 29.
    Corona G, Isidori AM, Buvat J, Aversa A, Rastrelli G, Hackett G, Rochira V, Sforza A, Lenzi A, Mannucci E, Maggi M. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. 2014;11:1577–92.CrossRefGoogle Scholar
  30. 30.
    Boloña ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, Caples SM, Erwin PJ, Montori VM. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:20–8.CrossRefGoogle Scholar
  31. 31.
    Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol. 2005;63:381–94.CrossRefGoogle Scholar
  32. 32.
    Rastrelli G, Maggi M, Corona G. Pharmacological management of late onset hypogonadism. Expert Rev Clin Pharmacol. 2018;11:439–58.CrossRefGoogle Scholar
  33. 33.
    Cohen J. Statistical power analysis for the behavioral sciences. New York: Academic Press; 1977.Google Scholar
  34. 34.
    Corona G, Rastrelli G, Filippi S, Vignozzi L, Mannucci E, Maggi M. Erectile dysfunction and central obesity: an Italian perspective. Asian J Androl. 2014;16:581–9.CrossRefGoogle Scholar
  35. 35.
    Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, Saad F, Mannucci E, Maggi M. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Investig. 2016;39:967–81.CrossRefGoogle Scholar
  36. 36.
    Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015;16:581–606.CrossRefGoogle Scholar
  37. 37.
    Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol. 2005;63:280–93.CrossRefGoogle Scholar
  38. 38.
    Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:29–39.CrossRefGoogle Scholar
  39. 39.
    Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560–75.CrossRefGoogle Scholar
  40. 40.
    Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, Saad F, Mannucci E, Maggi M. Therapy of endocrine disease: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174:R99–116.CrossRefGoogle Scholar
  41. 41.
    Golds G, Houdek D, Arnason T. Male hypogonadism and osteoporosis: the effects, clinical consequences, and treatment of testosterone deficiency in bone health. Int J Endocrinol. 2017;2017:4602129.  https://doi.org/10.1155/2017/4602129. Epub 2017 Mar 16CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Tracz MJ, Sideras K, Boloña ER, Haddad RM, Kennedy CC, Uraga MV, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 2006;91:2011–6.CrossRefGoogle Scholar
  43. 43.
    Smith JB, Rosen J, Colbert A. Low serum testosterone in outpatient psychiatry clinics: addressing challenges to the screening and treatment of hypogonadism. Sex Med Rev. 2018;6:69–76.CrossRefGoogle Scholar
  44. 44.
    Lv W, Du N, Liu Y, Fan X, Wang Y, Jia X, Hou X, Wang B. Low testosterone level and risk of Alzheimer’s disease in the elderly men: a systematic review and meta-analysis. Mol Neurobiol. 2016;53:2679–84.CrossRefGoogle Scholar
  45. 45.
    Wahjoepramono EJ, Asih PR, Aniwiyanti V, Taddei K, Dhaliwal SS, Fuller SJ, Foster J, Carruthers M, Verdile G, Sohrabi HR, Martins RN. The effects of testosterone supplementation on cognitive functioning in older men. CNS Neurol Disord Drug Targets. 2016;15:337–43.CrossRefGoogle Scholar
  46. 46.
    Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109–22.CrossRefGoogle Scholar
  47. 47.
    Vigen R, O’Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS, Ho PM. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829–36.CrossRefGoogle Scholar
  48. 48.
    Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF Jr, Hoover RN. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9:e85805.CrossRefGoogle Scholar
  49. 49.
    Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.CrossRefGoogle Scholar
  50. 50.
    Isidori AM, Balercia G, Calogero AE, Corona G, Ferlin A, Francavilla S, Santi D, Maggi M. Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Investig. 2015;38:103–12.CrossRefGoogle Scholar
  51. 51.
    Corona G, Sforza A, Maggi M. Testosterone replacement therapy: long-term safety and efficacy. World J Mens Health. 2017;35:65–76.CrossRefGoogle Scholar
  52. 52.
    Corona G, Vignozzi L, Sforza A, Maggi M. Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health. 2013;31:103–25.CrossRefGoogle Scholar
  53. 53.
    Elagizi A, Köhler TS, Lavie CJ. Testosterone and cardiovascular health. Mayo Clin Proc. 2018;93:83–100.CrossRefGoogle Scholar
  54. 54.
    Sharma R, Oni OA, Gupta K, Chen G, Sharma M, Dawn B, Sharma R, Parashara D, Savin VJ, Ambrose JA, Barua RS. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706–15.CrossRefGoogle Scholar
  55. 55.
    Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451–7.CrossRefGoogle Scholar
  56. 56.
    Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, Maggi M. Cardiovascular risk associated with testosterone boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13:1327–51.CrossRefGoogle Scholar
  57. 57.
    Borst SE, Shuster JJ, Zou B, Ye F, Jia H, Wokhlu A, Yarrow JF. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Med. 2014;12:211.CrossRefGoogle Scholar
  58. 58.
    Albert SG, Morley JE. Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review. Clin Endocrinol (Oxf). 2016;85:436–43.CrossRefGoogle Scholar
  59. 59.
    Alexander GC, Iyer G, Lucas E, Lin D, Singh S. Cardiovascular risks of exogenous testosterone use among men: a systematic review and meta-analysis. Am J Med. 2017;130:293–305.CrossRefGoogle Scholar
  60. 60.
    Corona G, Dicuio M, Rastrelli G, Maseroli E, Lotti F, Sforza A, Maggi M. Testosterone treatment and cardiovascular and venous thromboembolism risk: what is ‘new’? J Investig Med. 2017;65:964–73.CrossRefGoogle Scholar
  61. 61.
    Corona G, Gacci M, Baldi E, Mancina R, Forti G, Maggi M. Androgen deprivation therapy in prostate cancer: focusing on sexual side effects. J Sex Med. 2012;9(3):887–902.CrossRefGoogle Scholar
  62. 62.
    Corona G, Baldi E, Maggi M. Androgen regulation of prostate cancer: where are we now? J Endocrinol Investig. 2011;34:232–43.CrossRefGoogle Scholar
  63. 63.
    Lopez DS, Advani S, Tsilidis KK, Wang R, Canfield S. Endogenous and exogenous testosterone and prostate cancer: decreased-, increased- or null-risk? Transl Androl Urol. 2017;6:566–79.CrossRefGoogle Scholar
  64. 64.
    Cui Y, Zhang Y. The effect of androgen-replacement therapy on prostate growth: a systematic review and meta-analysis. Eur Urol. 2013;64:811–22.CrossRefGoogle Scholar
  65. 65.
    Cui Y, Zong H, Yan H, Zhang Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17:132–43.CrossRefGoogle Scholar
  66. 66.
    Guo C, Gu W, Liu M, Peng BO, Yao X, Yang B, Zheng J. Efficacy and safety of testosterone replacement therapy in men with hypogonadism: a meta-analysis study of placebo-controlled trials. Exp Ther Med. 2016;11:853–63.CrossRefGoogle Scholar
  67. 67.
    Kang DY, Li HJ. The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94:e410.CrossRefGoogle Scholar
  68. 68.
    Boyle P, Koechlin A, Bota M, d'Onofrio A, Zaridze DG, Perrin P, Fitzpatrick J, Burnett AL, Boniol M. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int. 2016;118:731–41.CrossRefGoogle Scholar
  69. 69.
    Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310–20.CrossRefGoogle Scholar
  70. 70.
    Rastrelli G, Corona G, Vignozzi L, Maseroli E, Silverii A, Monami M, Mannucci E, Forti G, Maggi M. Serum PSA as a predictor of testosterone deficiency. J Sex Med. 2013;10:2518–28.CrossRefGoogle Scholar
  71. 71.
    Corona G, Boddi V, Lotti F, Gacci M, Carini M, De Vita G, Sforza A, Forti G, Mannucci E, Maggi M. The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction. J Sex Med. 2010;7(1 Pt 1):284–92.CrossRefGoogle Scholar
  72. 72.
    Gacci M, Corona G, Apolone G, Lanciotti M, Tosi N, Giancane S, Masieri L, Serni S, Maggi M, Carini M. Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 2010;13:168–72.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • G. Rastrelli
    • 1
  • Y. Reisman
    • 2
  • S. Ferri
    • 3
  • O. Prontera
    • 3
  • A. Sforza
    • 3
  • M. Maggi
    • 1
  • G. Corona
    • 3
  1. 1.Sexual Medicine and Andrology Unit, Department of Experimental, Clinical and Biomedical SciencesUniversity of FlorenceFlorenceItaly
  2. 2.Department of UrologyAmstelland HospitalAmsterdamThe Netherlands
  3. 3.Endocrinology Unit, Medical DepartmentMaggiore-Bellaria HospitalBolognaItaly

Personalised recommendations